Video

Challenges of designing an AI platform for Drug Discovery w/ Marek Kultys

Biology is complicated. Our scientists work with large amounts of scientific data to better understand the relationship between biological entities.

Many of these pieces form a coherent picture about one segment of the biology in question, but often, scientists are presented with conflicting evidence. There are many gaps in the understanding of biology and many blanks remain to be filled. Understanding and filling these gaps is incredibly important for scientists to be able to select the right targets.  

At Benevolent we use various computational technologies and a range of standard and non-standard design patterns to help drug discoverers explore and select the best targets for validation. The role of our machine learning researchers, engineers and designers is to build this technology that helps our scientists break though this vastness of biological information to develop medicines for the patients that need them most.  

Marek, Lead Product Designer, gives a talk at World Usability Day Silesia 2019 in which explores the design process at BenevolentAI where he builds user facing tools that help our scientists discover and develop new medicines.

More Posts

You Might Also Like

News
BenevolentAI announces participation in upcoming investor conferences
BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.
Jun 10, 2022
News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022